Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson announced positive early-stage trial results for its experimental prostate cancer drug JNJ-6143, acquired through a $3.05 billion Halda Therapeutics deal. The drug demonstrated significant efficacy, with 77% of patients achieving a 50% reduction in PSA levels.